Prostate-specific membrane antigen antibody drug conjugates
US10800856B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2013 |
| Grant date | Oct 13, 2020 |
| Priority date | — |
| Expiry date | Jul 23, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/3069
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.